Metformin inhibits non-small cell lung cancer via lncRP11-242D8.1.
1/5 보강
[OBJECTIVES] Metformin may exert anticancer effects in non-small cell lung cancer (NSCLC) by influencing long non-coding RNAs involved in the disease's pathology.
APA
Tian X, Qiao Z, et al. (2026). Metformin inhibits non-small cell lung cancer via lncRP11-242D8.1.. Archives of biochemistry and biophysics, 778, 110751. https://doi.org/10.1016/j.abb.2026.110751
MLA
Tian X, et al.. "Metformin inhibits non-small cell lung cancer via lncRP11-242D8.1.." Archives of biochemistry and biophysics, vol. 778, 2026, pp. 110751.
PMID
41643885
Abstract
[OBJECTIVES] Metformin may exert anticancer effects in non-small cell lung cancer (NSCLC) by influencing long non-coding RNAs involved in the disease's pathology. The Study aimed to investigate the inhibitory effect of metformin on NSCLC by modulating the expression of lncRP11-242D8.1.
[METHODS] Inflammation and apoptosis levels in NSCLC were assessed at the molecular level using immunofluorescence, RT-qPCR, and ELISA. Metformin's effects on NSCLC in vitro were evaluated by CCK8, scratch wound healing, Transwell, colony formation, flow cytometry assays, etc. Bioinformatics analysis and molecular experiments were combined to investigate the mechanisms involving metformin and lncRP11-242D8.1.
[RESULTS] Low expression of lncRP11-242D8.1 is positively correlated with increased inflammation and decreased apoptosis, leading to poor prognosis in NSCLC. Treatment with metformin in the H1299 cell model improved this trend.
[CONCLUSION] This study suggests that metformin treats NSCLC by upregulating lncRP11-242D8.1 expression, which inhibits inflammation and promotes apoptosis, offering a new perspective for clinical treatment.
[METHODS] Inflammation and apoptosis levels in NSCLC were assessed at the molecular level using immunofluorescence, RT-qPCR, and ELISA. Metformin's effects on NSCLC in vitro were evaluated by CCK8, scratch wound healing, Transwell, colony formation, flow cytometry assays, etc. Bioinformatics analysis and molecular experiments were combined to investigate the mechanisms involving metformin and lncRP11-242D8.1.
[RESULTS] Low expression of lncRP11-242D8.1 is positively correlated with increased inflammation and decreased apoptosis, leading to poor prognosis in NSCLC. Treatment with metformin in the H1299 cell model improved this trend.
[CONCLUSION] This study suggests that metformin treats NSCLC by upregulating lncRP11-242D8.1 expression, which inhibits inflammation and promotes apoptosis, offering a new perspective for clinical treatment.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Combined fluorescein sodium and intraoperative ultrasound enhance resection and functional outcomes in high-grade glioma surgery.
- Active-site rich nanostructure with dual-enhanced electron transfer for ultra-sensitive electrochemiluminescence detection of DNA methylation in colon cancer.
- Neutrophil Extracellular Traps in Cancer Metastasis: From Mechanistic Understanding to Targeted Therapy.
- Corrigendum to "Metformin inhibits non-small cell lung cancer via lncRP11-242D8.1" [Archives of Biochemistry and Biophysics. 778C (2026) 110751].
- hnRNPA3 promotes the proliferation of hepatocellular carcinoma cells by stabilizing GLI2 proteins and activating Hedgehog pathway.